PERSPECTA

News from every angle

← Back to headlines

Soligenix Advances CTCL Research with Interim Analysis

Soligenix (NASDAQ: SNGX) has announced progress in its Cutaneous T-Cell Lymphoma (CTCL) research, presenting results from an interim analysis and comparative study.

18 Apr, 17:59 — 18 Apr, 17:59
PostShare

Sources

Showing 1 of 1 sources
globe-and-mailHigh22h ago

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results - The Globe and Mail

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results  The Globe and Mail

Read full article →

Related Stories

Rat Poison Found in HiPP Baby Food in Austria, Police Suspect Blackmail

just now

Rat Poison Found in HiPP Baby Food Across Central Europe; Blackmail Suspected

just now

Medical Students in Niš Announce Protest

13m ago

Eight Children Killed in Louisiana Domestic Violence Shooting

16m ago